Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

Affiliations

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan. kawakami_h@med.kindai.ac.jp.
² Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
³ Cancer Center, Gifu University Hospital, Gifu, Japan.
⁴ Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
⁵ Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
⁶ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
⁷ Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁸ Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
⁹ Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan.
¹⁰ Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
¹¹ Oncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
¹² Data Intelligence Department, Daiichi Sankyo Co. Ltd., Tokyo, Japan.

Published Erratum

Hisato Kawakami et al. Gastric Cancer. 2025 Jan.

. 2025 Jan;28(1):62.

doi: 10.1007/s10120-024-01570-x.

¹ Department of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan. kawakami_h@med.kindai.ac.jp.
² Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
³ Cancer Center, Gifu University Hospital, Gifu, Japan.
⁴ Division of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
⁵ Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
⁶ Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
⁷ Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan.
⁸ Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
⁹ Department of Surgery, Kindai University Faculty of Medicine, Osakasayama, Japan.
¹⁰ Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
¹¹ Oncology Medical Science Department I, Daiichi Sankyo Co. Ltd., Tokyo, Japan.
¹² Data Intelligence Department, Daiichi Sankyo Co. Ltd., Tokyo, Japan.

No abstract available

Erratum for

Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study).
Kawakami H, Nakanishi K, Makiyama A, Konishi H, Morita S, Narita Y, Sugimoto N, Minashi K, Imano M, Inamoto R, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K; EN-DEAVOR Study Group. Kawakami H, et al. Gastric Cancer. 2025 Jan;28(1):51-61. doi: 10.1007/s10120-024-01555-w. Epub 2024 Oct 10. Gastric Cancer. 2025. PMID: 39387986 Free PMC article.